• Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO®

    7 days ago - By San Diego Biotechnology

    CAMBRIDGE, Mass.--Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today positive early results on clinical outcome measures from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO® , an RNAi therapeutic targeting hydroxyacid oxidase 1 - the gene encoding glycolate oxidase - for...
    Read more ...